Literature DB >> 12825961

Therapeutic strategies in common variable immunodeficiency.

W A Carrock Sewell1, Matthew Buckland, Stephen R A Jolles.   

Abstract

The treatment of common variable immunodeficiency (CVID) is currently based on the early recognition of the condition and replacement immunoglobulin combined with prompt treatment of infections and complications. The route of administration, dose and frequency of administration of immunoglobulin still vary between centres and countries. Other interventions aimed at overcoming the immunological defects in CVID such as interleukin-2 therapy are being studied but there is as yet insufficient evidence to support their routine use. The treatment of complications such as suppurative lung disease uses principles broadly similar to those used for cystic fibrosis, whereas the granulomatous complications involving the lungs and other organ systems are in need of much more research to define optimum therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825961     DOI: 10.2165/00003495-200363130-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  103 in total

1.  Up-regulation of IL-12 in monocytes: a fundamental defect in common variable immunodeficiency.

Authors:  R Cambronero; W A Sewell; M E North; A D Webster; J Farrant
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  ICOS co-stimulatory receptor is essential for T-cell activation and function.

Authors:  C Dong; A E Juedes; U A Temann; S Shresta; J P Allison; N H Ruddle; R A Flavell
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

Review 3.  Lymphocyte surface phenotype in common variable immunodeficiency.

Authors:  G P Spickett; N Matamoros; J Farrant
Journal:  Dis Markers       Date:  1992 Mar-Apr       Impact factor: 3.434

4.  High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease.

Authors:  C M Roifman; H Levison; E W Gelfand
Journal:  Lancet       Date:  1987-05-09       Impact factor: 79.321

5.  Mutations in the mu heavy-chain gene in patients with agammaglobulinemia.

Authors:  L Yel; Y Minegishi; E Coustan-Smith; R H Buckley; H Trübel; L M Pachman; G R Kitchingman; D Campana; J Rohrer; M E Conley
Journal:  N Engl J Med       Date:  1996-11-14       Impact factor: 91.245

6.  The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial.

Authors:  H W Eijkhout; J W van Der Meer; C G Kallenberg; R S Weening; J T van Dissel; L A Sanders; P F Strengers; H Nienhuis; P T Schellekens
Journal:  Ann Intern Med       Date:  2001-08-07       Impact factor: 25.391

7.  Treatment of resistant mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic.

Authors:  C Heilmann; L Jensen; J S Jensen; K Lundstrom; D Windsor; H Windsor; D Webster
Journal:  J Infect       Date:  2001-11       Impact factor: 6.072

8.  Immunological aspects of retinoids in humans. I. Analysis of retinoic acid enhancement of thymocyte responses to PHA.

Authors:  N Sidell; P Rieber; S H Golub
Journal:  Cell Immunol       Date:  1984-08       Impact factor: 4.868

9.  A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID).

Authors:  J A Rump; A Jahreis; M Schlesier; S Stecher; H H Peter
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

10.  Intravenous immunoglobulin therapy for antibody deficiency.

Authors:  M T Nolte; B Pirofsky; G A Gerritz; B Golding
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

View more
  6 in total

1.  Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.

Authors:  Eleanor Roy; Evangelos Stavropoulos; John Brennan; Stephen Coade; Elena Grigorieva; Barry Walker; Belinda Dagg; Ricardo E Tascon; Douglas B Lowrie; M Joseph Colston; Stephen Jolles
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 2.  Intravenous immunoglobulin in immunodeficiency states: state of the art.

Authors:  Elias Toubi; Amos Etzioni
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  [29-year-old female patient with pneumonia and enlarged abdominal lymph nodes].

Authors:  F Kuchenbauer; T Ngo; A Muth; O Stötzer; E Hiller
Journal:  Internist (Berl)       Date:  2005-08       Impact factor: 0.743

Review 4.  Common variable immunodeficiency: etiological and treatment issues.

Authors:  Sean Deane; Carlo Selmi; Stanley M Naguwa; Suzanne S Teuber; M Eric Gershwin
Journal:  Int Arch Allergy Immunol       Date:  2009-07-01       Impact factor: 2.749

5.  Major approaches in early diagnostics of common variable immunodeficiency in adults in Moscow.

Authors:  Alexander V Karaulov; Irina V Sidorenko; Anna S Kapustina
Journal:  F1000Res       Date:  2012-11-09

6.  An unsual case of persistent inguinal swelling - beware immunodeficiency.

Authors:  Robin Som; Sarah Milton-White; James A Gossage; Paul Rowe
Journal:  JRSM Short Rep       Date:  2011-11-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.